Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
•
Medical Oncology
Would you offer chemotherapy to a young female s/p TAH-BSO with a pure mucinous, grade 3, T1cN0, HR+ HER2- breast cancer and an OncotypeDx score between 21-25?
Oncotype 24, <50 years old.
Related Questions
How would you approach the treatment of low grade, stage IA, triple negative apocrine adenocarcinoma of the breast in a female patient in her 70s?
Does delay to the time of lumpectomy impact your decision to omit radiation?
What are your top takeaways in Breast Cancer from ESMO 2024?
Does pre-chemotherapy extent of nodal involvement impact your decision to offer adjuvant radiation in cN1, ypN0 triple-negative breast cancer?
What is your preferred method of surveillance after mastectomy?
In cT4aN0 triple negative breast cancer would you still recommend PMRT if pCR, ypT0N0(sn), after neoadj chemo is achieved?
How do the results of INSEMA and SOUND impact the decision of omitting SLND in young women with breast cancer and offering adjuvant RT to patients who would otherwise be candidates for omission?
What are your top takeaways in Radiation Oncology from SABCS 2024?
Do you recommend self-breast exams to your patients with history of breast cancer in addition to imaging surveillance?
How would you approach radiation for an elderly patient with pT2N1 TNBC s/p MRM and ALND who refused chemo-immunotherapy?